+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Non-Hodgkin Lymphoma Therapeutics - Global Strategic Business Report

  • PDF Icon

    Report

  • 192 Pages
  • July 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309797
The global market for Non-Hodgkin Lymphoma Therapeutics is estimated at US$11.1 Billion in 2023 and is projected to reach US$17.8 Billion by 2030, growing at a CAGR of 7% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Immunotherapy segment, which is expected to reach US$9.1 Billion by 2030 with a CAGR of a 7.5%. The Targeted Therapy segment is also set to grow at 6.8% CAGR over the next 7 years.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $3.4 Billion in 2023, and China, forecasted to grow at an impressive 6.6% CAGR to reach $3.1 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Non-Hodgkin Lymphoma Therapeutics Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Non-Hodgkin Lymphoma Therapeutics Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Non-Hodgkin Lymphoma Therapeutics Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 38 Featured):

  • Bayer AG
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.

MarketGlass Platform

Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Non-Hodgkin Lymphoma Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Global Economic Update
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Non-Hodgkin Lymphoma Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 3: World Historic Review for Non-Hodgkin Lymphoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 4: World 16-Year Perspective for Non-Hodgkin Lymphoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 6: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 7: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Targeted by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 9: World Historic Review for Targeted by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 10: World 16-Year Perspective for Targeted by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 12: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 13: World 16-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Non-Hodgkin Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 14: USA Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 15: USA Historic Review for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 16: USA 16-Year Perspective for Non-Hodgkin Lymphoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted and Other Therapies for the Years 2014, 2024 & 2030
CANADA
  • Table 17: Canada Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 18: Canada Historic Review for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 19: Canada 16-Year Perspective for Non-Hodgkin Lymphoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted and Other Therapies for the Years 2014, 2024 & 2030
JAPAN
  • Non-Hodgkin Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 20: Japan Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 21: Japan Historic Review for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 22: Japan 16-Year Perspective for Non-Hodgkin Lymphoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted and Other Therapies for the Years 2014, 2024 & 2030
CHINA
  • Non-Hodgkin Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 23: China Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 24: China Historic Review for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 25: China 16-Year Perspective for Non-Hodgkin Lymphoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted and Other Therapies for the Years 2014, 2024 & 2030
EUROPE
  • Non-Hodgkin Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 26: Europe Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 27: Europe Historic Review for Non-Hodgkin Lymphoma Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 28: Europe 16-Year Perspective for Non-Hodgkin Lymphoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 29: Europe Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 30: Europe Historic Review for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 31: Europe 16-Year Perspective for Non-Hodgkin Lymphoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted and Other Therapies for the Years 2014, 2024 & 2030
FRANCE
  • Non-Hodgkin Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 32: France Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 33: France Historic Review for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 34: France 16-Year Perspective for Non-Hodgkin Lymphoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted and Other Therapies for the Years 2014, 2024 & 2030
GERMANY
  • Non-Hodgkin Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 35: Germany Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 36: Germany Historic Review for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 37: Germany 16-Year Perspective for Non-Hodgkin Lymphoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted and Other Therapies for the Years 2014, 2024 & 2030
ITALY
  • Table 38: Italy Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 39: Italy Historic Review for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 40: Italy 16-Year Perspective for Non-Hodgkin Lymphoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted and Other Therapies for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Non-Hodgkin Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 41: UK Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 42: UK Historic Review for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 43: UK 16-Year Perspective for Non-Hodgkin Lymphoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted and Other Therapies for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 44: Rest of Europe Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 45: Rest of Europe Historic Review for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 46: Rest of Europe 16-Year Perspective for Non-Hodgkin Lymphoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted and Other Therapies for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Non-Hodgkin Lymphoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 47: Asia-Pacific Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 48: Asia-Pacific Historic Review for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 49: Asia-Pacific 16-Year Perspective for Non-Hodgkin Lymphoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted and Other Therapies for the Years 2014, 2024 & 2030
REST OF WORLD
  • Table 50: Rest of World Recent Past, Current & Future Analysis for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 51: Rest of World Historic Review for Non-Hodgkin Lymphoma Therapeutics by Therapy - Immunotherapy, Targeted and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 52: Rest of World 16-Year Perspective for Non-Hodgkin Lymphoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted and Other Therapies for the Years 2014, 2024 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Bayer AG
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.

Table Information